Amicus Therapeutics, Inc. (FOLD)

Overview

Amicus Therapeutics, Inc. is a pioneering biotechnology entity dedicated to the mission of discovering, developing, and delivering medicinal solutions for rare diseases. This company has carved a niche for itself in the healthcare sector by focusing on the unmet medical needs of the rare disease community. Established in 2002 and having its headquarters in Princeton, New Jersey, Amicus Therapeutics has been at the forefront of addressing some of the most challenging and underserved medical conditions. Through its strategic collaborations and license agreements with esteemed institutions like the University of Pennsylvania and industry giants like GlaxoSmithKline, Amicus has expanded its research and development capabilities to include innovative gene therapy products, furthering its commitment to the rare disease community.

Products and Services

• Galafold

  This is an oral precision medicine developed by Amicus Therapeutics for the treatment of adults with a confirmed diagnosis of Fabry disease who have an amenable galactosidase alpha gene variant. Galafold represents a significant advancement in the treatment of this genetic disorder, offering a targeted approach that addresses the underlying cause of the disease.

• Pombiliti + Opfolda

  Designed for the treatment of late onset Pompe disease, Pombiliti + Opfolda is part of Amicus Therapeutics' commitment to broadening its portfolio to address a wider range of rare diseases. This development reflects the company's ongoing efforts and investment in research geared towards improving the quality of life for individuals affected by rare genetic disorders.